#3 - Regeneron (NASDAQ:REGN)
Regeneron (NASDAQ:REGN) and Sanofi currently collaborate on Kevzara (for the treatment of rheumatoid arthritis) and Praluent (for the treatment of high cholesterol). The drug is being evaluated for its potential use in helping reduce inflammation in the lungs for patients with more severe cases of the coronavirus. The company anticipates receiving initial results within a few weeks of when patients become enrolled in the Kevzara study.
Regeneron is working separately on a “cocktail” of viral-neutralizing antibodies. The company believes that clinical testing could begin in early summer. “In order to meet the pressing public health need, Regeneron is applying its VeociMab technology to prepare manufacturing-ready cell line as lead antibodies are selected, so that clinical-scale production can being immediately,” a company spokesperson said.
If effective, it’s possible the cocktail can be administered prior to exposure to protect against infection. "The company is working toward the goal of producing hundreds of thousands of prophylactic doses per month by the end of summer and hopes to have smaller quantities available for initial clinical testing at the beginning of the summer."
Shares of REGN stock are up over 25% in 2020.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More - Current Price
- $967.98
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 16 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $989.36 (2.2% Upside)
